Mode
Text Size
Log in / Sign up
Phase 4 N=103 Randomized Triple-blind Treatment

Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy

Pain, Postoperative · Analgesics, Opioid · Analgesics, Non-Narcotic · Physiological Effects of Drugs · Peripheral Nervous System Agents

Enrolled (actual)
103
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcome: Primary: Change in Pain Score — 4.20; 4.62 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Abdominal wall block with liposomal bupivicaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of California, Los Angeles
Primary completion
Jun 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Pain Score
4.20; 4.62
SECONDARY
Patient Satisfaction With Pain Management
8.6; 9.1
SECONDARY
Nausea and Vomiting, Defined as Requiring Pre-op Scopolamine Patch or Rescue Antiemetics
9; 11; 6; 8
SECONDARY
Return of Bowel Function
1.9; 1.9
SECONDARY
Participants Experiencing Complications Related to Surgery or Block
5; 3
SECONDARY
Opioid Use Dose/Day
11; 9; 6; 8; 3; 8

Summary

A blinded randomized control trial in living kidney donors. The study group will receive a liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general anesthesia. The following study variables will be collected postoperatively following arrival in the post-anesthesia care unit. Current and maximum intensity pain scores will be documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24 hours will be collected from the EHR and pain diary after discharge. Patient satisfaction will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing notes.

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing laparoscopic donor nephrectomy

Exclusion Criteria

  • Pregnancy
  • Systemic or local infection at the potential block site.
  • Allergy or hypersensitivity to the local anesthetic,
  • Possible variations in surgical approach to donor nephrectomy other than what is defined in this protocol.
  • Scarring or anatomic abnormality over the proposed injection site
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03294109). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search